14-0839-82

antibody from Invitrogen Antibodies

Targeting: CD83 BL11, HB15

Antibody data

Submit

Validation data

Product number: 14-0839-82 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD83 Monoclonal Antibody (HB15e), eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The HB15e monoclonal antibody reacts with human CD83, a 45 kDa transmembrane glycoprotein. CD83, a member of the Ig superfamily, is expressed on cultured dendritic cells, interdigitating, follicular, and circulating dendritic cells as well as some proliferating lymphocytes, and human cell lines express this antigen. While the function of CD83 is unclear, it can serve as a useful marker for mature human blood dendritic cells.
Antibody clone number: HB15e
Concentration: 0.5 mg/mL

CD83 protein structure - 14-0839-82 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 4 PDDCs are immature, but accessory molecule expression can be induced. PDDCs were generated at 24 h and measured by flow cytometry for the accessory molecules CD83, CD86, CD40, and HLA-DR. (A) mfa-1 + PDDCs (Pg381, DPG-3) displayed a low, natural expression of accessory molecules. mfa1 - PDDCs had significantly higher levels of CD83, whereas all PDDC groups had significantly elevated CD40 surface expression. (B) When PDDCs were subsequently matured, CD83 and CD86 surface expression was significantly lower in all of the infected groups compared with mature MoDCs. All PDDC groups had significantly elevated CD40 surface expression after maturation compared with MoDCs. P P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Expression of maturation and activation marker CD83 and CD86 by the three DC types. a Isotype control staining (left column), followed by surface marker staining of non-stimulated (medium, shown in the middle) or LPS-stimulated (right column) moDCs (top), RAmoDCs (middle) and TGFmoDCs (bottom) are displayed. b Mean percentage, MFI and standard error are shown of 4 different donors after 48 h of incubation with medium or bacterial ligands. c p values of t test between DC subsets after activation with bacterial ligands. Statistical differences between DC subtypes are shown (t test). Similar results (not shown) were obtained with DCs stimulated for 24 h from 3 independent donors.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Identification of a gene expression signature linked to early dissemination. A Microarray time-series data analysis was performed on cells after treatment with BM-MSC-CM at 9 time points, from 0 to 96 h. Representative clusters of the indicated genes are shown as heatmaps, with red indicating increased expression and green indicating decreased expression, as indicated by the color intensity scale shown below each heatmap. B Functional fractionation of A549 cells via invasion assays. The percentage of cells expressing surface markers was determined by flow cytometry (CD133 + /CD83 + for early-response cells; CD151 + /CD38 + for late-response cells). C - E Functional fractionation of cancer cells via serial invasion assays. Cells were serially selected through 5 (HM5), 10 (HM10), or 20 (HM20) Matrigel invasion assays. The percentage of cells expressing surface markers was determined by QPCR (CD133 + /CD83 + in D ; CD151 + /CD38 + in E ). F QPCR showing the mRNA expression levels of STAT3 signaling-related genes. HM20 cells are compared to LM cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Effect of E. purpurea on CD83 expression in various cell cultures. (A): Flow cytometry showing the expression of CD83. Monocyte-derived DCs were generated in presence or absence of E. purpurea . (Group A) control group; (Group B) E. purpurea (500 mug/ml) on day 7; (Group C) TNF-alpha (10 ng/ml) on day 7 + E. purpurea (500 mug/ml) on day 8; (Group D) E. purpurea (500 mug/ml) on day 7 + TNF-alpha (10 ng/ml) on day 8; (Group E) E. purpurea (500 mug/ml) on day 0 + TNF-alpha (10 ng/ml) on day 7. (B): Percentage of DCs expressing CD83 in different groups. Expression of CD83 cell marker is measured by BD FACSCalibur(r). Each value is the mean of 3 experiments +- SE. * P < 0.05.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 PA T encounter with DCs results in limited activation involving upregulation of Il2 and Bcl2 . (A) PA T cells were co-cultured with DC1940 for 24 h, then CD4 + populations were gated into CD69 + and CD69 - cells by FACS. The expression of CD103, CXCR5, CD62L, CCR9, CCR7, CD127 and CD83 between CD69 + and CD69 - cells were compared. Three replicates in each group ( n = 3), and results are representative of three independent experiments ( N = 3). (B) CD69 + and CD69 - cells cultured in complete RPMI for 24 h without additional treatment, then the cytokines released to the supernatant were measured by ELISA. Pooled data from three independent experiments are shown. (C) Gene expression of Il7r , Il2 and Bcl2 was determined by QPCR in PA T cells or in CD69 positive or negative populations purified by FACS sorting. Three replicates in each group ( n = 3), and results are representative of three independent experiments ( N = 3). GAPDH was used for normalization